Lundbeck Is Said To Express Interest In Buying Xeris Biopharma, Bloomberg Reports

Lundbeck has reportedly expressed interest in acquiring Xeris Biopharma, according to Bloomberg. This potential acquisition could impact the market for Xeris, which trades under the ticker XERS. Further details regarding the financial terms or strategic implications of the deal have not been disclosed.